

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Obeticholic acid for treating liver fibrosis in people with non-alcoholic steatohepatitis ID1645

Provisional stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Intercept Pharmaceuticals (obeticholic acid) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Addenbrookes Liver Transplant Association • British Liver Trust • Hepatitis B Foundation UK • Hepatitis C Trust • Lifeline Project • Liver4Life • Muslim Council of Great Britain • South Asian Health Foundation • Specialised Healthcare Alliance <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • Association of Surgeons of Great Britain and Ireland • British Association for the Study of the Liver • British Blood Transfusion Society • British Committee for Standards in Haematology • British Geriatric Society • British Infection Association • British Liver Nurses Forum • British Society for Gastroenterology • British Society for Haematology • British Viral Hepatitis Group • Hepatitis Nurse Specialist Forum • NHS Blood and Transplant • Positive Prevention Plus • Royal College of Anaesthetists • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists 	<p><u>General</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Hospital Information Services - Jehovah's Witnesses • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Possible comparator companies</u></p> <ul style="list-style-type: none"> • Actavis UK (pioglitazone) • AAH Pharmaceuticals (pioglitazone) • Accord Healthcare (pioglitazone) • Alliance Healthcare (pioglitazone) • Brown & Burk UK (pioglitazone) • Consilient Health (pioglitazone) • DE Pharmaceuticals (pioglitazone) • Mawdsley-Brooks & Company (pioglitazone) • Morningside Healthcare (pioglitazone) • Mylan (pioglitazone) • Sigma Pharmaceuticals (pioglitazone) • Teva UK (pioglitazone)

Provisional stakeholder list for the proposed technology appraisal of obeticholic acid for treating liver fibrosis in people with non-alcoholic steatohepatitis ID1645. Issue date: January 2020

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Royal College of Physicians • Royal College of Surgeons • Royal Pharmaceutical Society • UK Clinical Pharmacy Association • UK Clinical Virology Network • UK Harm Reduction Alliance <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS Bexley CCG • NHS England • NHS West London CCG • Welsh Government 	<ul style="list-style-type: none"> • Torrent Pharma (UK) (pioglitazone) • Takeda (pioglitazone) <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Hepato-Biliary Group • Cochrane Infectious Diseases group • Foundation for Liver Research • Genomics England • MRC Clinical Trials Unit • National Institute for Health Research • UK National Screening Committee <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality and eliminating unlawful discrimination.

Please let us know if we have missed any important organisations from the provisional stakeholder list and which organisations we should include who have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹ Non-company consultees are invited to submit statements relevant to the group they are representing.